Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The insect gamma-aminobutyric acid (GABA) receptor is a ligand-gated ion channel that mediates the majority of inhibitory neurotransmission in the insect central nervous system (Hosie et al., 1997). It belongs to the Cys-loop receptor superfamily and is typically composed of five subunits arranged around a central chloride-conducting pore, with the Resistance to dieldrin (RDL) subunit being the most prominent (Ffrench-Constant et al., 1993). Upon the binding of GABA, the receptor undergoes a conformational change that opens the pore, allowing chloride ions to enter the neuron and cause hyperpolarization, thereby dampening neuronal excitability (Bloomquist, 2003). This receptor is a critical target for several major classes of insecticides, including phenylpyrazoles like fipronil and the newer isoxazolines such as fluralaner (Gassel et al., 2014). These compounds act as non-competitive antagonists by binding to an allosteric site within the channel pore, effectively blocking chloride conductance and leading to lethal hyperexcitation of the insect's nervous system (Casida & Durkin, 2013). While these receptors share structural similarities with mammalian GABA-A receptors, significant sequence divergence allows for high insecticidal selectivity, which is exploited in both agricultural pest management and veterinary treatments for ectoparasites (Sattelle et al., 2008). Mutations in the RDL gene, particularly at the alanine 302 position, are well-documented biomarkers for insecticide resistance in various pest species (Ffrench-Constant, 2013).
Non-competitive antagonism of the GABA-gated chloride channel (IRAC Group 2 and 30) (Casida & Durkin, 2013)
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Insect gamma-aminobutyric acid receptor (iGABAR) (iGABAR).